Update: BCBSIL Approach to OTC COVID-19 Testing Coverage
This week the federal government released guidance about coverage of over-the-counter (OTC) COVID-19 diagnostic tests that takes effect Jan. 15, 2022.
The impact:
Coverage for at-home COVID-19 diagnostic OTC tests is required for all Blue Cross and Blue Shield of Illinois (BCBSIL) fully insured and self-insured groups, and individual and family plans.
Group health plans and issuers are required to cover COVID-19 diagnostic OTC tests without a prescription or health assessment from a provider.
BCBSIL will cover COVID-19 diagnostic OTC tests through our extensive network of participating pharmacies for our fully insured members and self-insured group members who have Prime Therapeutics® coverage through BCBSIL.
File is in portable document format (PDF). To view this file, you may need to install a PDF reader program. Most PDF readers are a free download. One option is Adobe® Reader® which has a built-in screen reader. Other Adobe accessibility tools and information can be downloaded at http://access.adobe.com.
By clicking this link, you will go to a new website/app (“site“). This new site may be offered by a vendor or an independent third party. The site may also contain non-Medicare related information. In addition, some sites may require you to agree to their terms of use and privacy policy.
Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association
File is in portable document format (PDF). To view this file, you may need to install a PDF reader program. Most PDF readers are a free download. One option is Adobe® Reader® which has a built-in screen reader. Other Adobe accessibility tools and information can be downloaded at